The Promise of Anti-ErbB3 Monoclonals as New Cancer Therapeutics

Oncotarget - United States
doi 10.18632/oncotarget.550
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy